Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1.

Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases.

Following a Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.

We are currently preparing to initiate a First-in-Human clinical oncology study with our lead antibody, MDX-124, later this year. Our non-clinical therapeutic development programme for autoimmune diseases continues in parallel.

 

Medannex won both ‘Investment of the Year’ and ‘Outstanding Skills Development’ at Scotland’s Life Sciences Annual Awards 2021.

 

Medannex is a proud signatory of the Scottish Business Pledge, showing our commitment to building sustainable growth whilst maintaining fairness, equality, opportunity and innovation.

more

Meet the Team

Meet the people delivering the Medannex company vision. more

Latest News

15.04.21Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021
25.03.21Medannex sweeps the board at Scotland’s Life Sciences Annual Awards
05.01.21Medannex team grows to 12 employees, as preparations for First-in-Human study gather pace
16.12.20Medannex chosen by Welp Magazine as a company to watch in the UK Clinical Trials space
view all news

“Medannex has identified a novel and promising target for immunotherapy, and I am delighted to offer guidance as the company prepares for its First-in-Human study.”

Dr Stefan Symeonides,
head of Phase I Trials at the CRUK Edinburgh Centre

Collaborations & Affiliations

Medannex is proud to collaborate with leading academic researchers, play an active role within several industry associations and provide extensive skills development opportunities.